Cash Equivalents and Marketable Securities: $588 million at year-end 2024, up from $239 million at December 31, 2023. Loss from Operations: $241.4 million for the year ending December 31, 2024, compared to $179.7 million in 2023. Cost of Sales: $11.4 million following BLA approval for obe-cel. Research and Development Expenses: $138.4 million for the year